Top
NewsChange the future
with cell therapy
Our aim is to develop new cell therapies
using “hematopoietic stem cells”.
Hematopoietic stem cells (HSCs) are the stem cells that are the very source of blood.
Our aim is to develop new cell therapies in order to treat blood cancer,
intractable blood diseases and genetic disorders.
The development of new cell therapies in the fight against leukemia and other blood cancers and genetic disorders
We are working on the development of next-generation cell therapy products that will utilize the unique properties of umbilical cord blood and peripheral blood, by expanding them in large quantities.
Successful in-vitro expansion of functional hematopoietic stem cells
We have succeeded in developing technology for the mass propagation of functional HSCs with blood reconstruction ability. In addition, since the technology does not use animal-derived components such as albumin and cytokines, HSCs can be propagated in large quantities with high quality and at low cost.
A growing need for the application of HSCs in cell therapy
In addition to providing new therapeutic options for the HSC transplantation treatments that are being performed today, we are also working on applications in the field of gene therapy, which has seen much active development in recent years.
-
financing
Celaid Therapeutics Completes Second Close of Series B Financing Round
-
newsParticipation in the Cell & Gene Meeting on the Mesa 2026
-
newsCelaid Therapeutics at BioJapan 2026
-
R&DCLD-001 Development Program Passes Second AMED Stage-Gate Review and Advances to Stage 3
-
newsSpeaking at LINK-J FESTIVAL 2026
-
newsSpeaking at TECHNIUM Global Conference 2026